Work

Cancer-associated histone mutation H2BG53D disrupts DNA–histone octamer interaction and promotes oncogenic phenotypes

Year: 2020
Type: article
Abstract: Recent studies from us and others have deciphered the clinical relevance of a variety of oncohistones 1 in different diseases. The H3K27M and H3K36M mutant histones exert dominant-negative effects on methylation levels of histone H3K27 and H3K36 on wild-type histone protein in pediatric brain cancers 2 , 3 , 4 and chondroblastoma, 5 , 6 respectively. In contrast to H3K27M and H3K36M that act in trans to cause global reduction of methylation at the respective residues, the H3G34 mutations, including H3G34V/R and H3G34W/L found in pediatric high-grade glioma and giant cell tumor of the bone, affect the H3K36 methylation in cis and alter the H3K36 methylation on the nucleosome containing the H3G34 mutation(s). In addition to histone H3, two recent reports revealed another class of oncogenic mutation in histone H2B. 7 , 8 The glutamic acid at position 76 of H2B was found to be replaced by lysine in multiple cancers, including breast and lung carcinomas. Cells expressing the H2BE76K mutation acquired oncogenic phenotypes as a result of aberrant gene expression associated with cancer pathways, an effect possibly due to the destabilization of the histone octamer by H2BE76K. Together, these studies indicated that missense mutations in histone genes impact gene expression and play a vital role in driving tumorigenesis by distinct mechanisms.
Language: English
Open Access status: gold
Estimated APC paid: $2,680
OpenAlex ID: W3010569736
FWCI: 1.246
Cites: 11
Cited by: 30
Related to: 10